These results suggest that CPO treatment suppresses the LCSC properties and CD133+ HCC cell population by destabilizing CD133 in CD133+ HCC cells; thereby CPO facilitates in vivo therapeutic efficiency in HCC. This evidence concerns the gene CPO and hepatocellular carcinoma.